3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
444
Neoplasms, Plasma Cell
77
Recurrence
62
Lymphoma
52
Lymphoma, Non-Hodgkin
48
Leukemia
43
Hodgkin Disease
43
Leukemia, Myeloid, Acute
42
Myelodysplastic Syndromes
37
Leukemia, Lymphocytic, Chronic, B-Cell
35
Precursor Cell Lymphoblastic Leukemia-Lymphoma
34
Lymphoma, Mantle-Cell
29
Lymphoma, Large B-Cell, Diffuse
29
Lymphoma, Follicular
27
Hematologic Neoplasms
24
Burkitt Lymphoma
24
Immunoglobulin Light-chain Amyloidosis
22
Myeloproliferative Disorders
21
Lymphoma, B-Cell, Marginal Zone
21
Waldenstrom Macroglobulinemia
18
Lymphoma, Large-Cell, Immunoblastic
18
Neoplasms
17
Lymphoma, T-Cell, Cutaneous
16
Lymphoma, Large-Cell, Anaplastic
14
Leukemia, Myelomonocytic, Chronic
14
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
14
Sezary Syndrome
13
Mycosis Fungoides
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
12
Leukemia, Myeloid, Accelerated Phase
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
GATA2 Deficiency
×
Plasma cell
×
Clear all
NCT03018405
2019-09-19
THINK
Celyad Oncology SA
Phase 1/2
Unknown
146 enrolled